GlassScriptPhysician profile
Joshua Krasnow
NPI 1114986205
$6,235.81
in general payments reported to CMS, 2019-2025
29 companies · $262 in 2025
The $262 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,441 · 2020: $354 · 2021: $947 · 2022: $863 · 2023: $1,588 · 2024: $780 · 2025: $262.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,631.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,630.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,318.15 | 2020-2025 | Xience Skypoint, Coroflow, Optis |
| Pfizer INC. | $495.97 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $470.15 | 2019-2023 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $410.86 | 2019-2023 | Farxiga, Brilinta |
| Novartis Pharmaceuticals Corporation | $346.67 | 2019-2023 | |
| Amgen INC. | $325.65 | 2019-2023 | Repatha |
| E.R. Squibb & Sons, L.L.C. | $283.93 | 2019-2023 | Camzyos, Eliquis |
| Gilead Sciences, INC. | $181.98 | 2019 | |
| Stryker Corporation | $175.73 | 2025 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Novo Nordisk INC | $132.23 | 2022-2023 | Ozempic, Rybelsus |
| Boston Scientific Corporation | $116.06 | 2019-2023 | Lux-Dx Insertable Cardiac Monitor |
| Medtronic, INC. | $115.18 | 2024 | Penditure, Onyx Frontier |
| Otsuka America Pharmaceutical, INC. | $111.43 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $104.41 | 2019-2020 | |
| Cardiovascular Systems INC. | $103.43 | 2019-2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $93.30 | 2022-2023 | Verquvo |
| Regeneron Healthcare Solutions, INC. | $85.10 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $68.09 | 2019 | |
| Penumbra, INC. | $64.23 | 2025 | Indigo System |
| Cmp Pharma, INC. | $50.11 | 2023 | Tadliq, Norliqva, Carospir |
| Esperion Therapeutics, INC. | $36.72 | 2020-2023 | Nexletol |
| Bayer Healthcare Pharmaceuticals INC. | $32.66 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $29.17 | 2023 | Lifevest |
| Actelion Pharmaceuticals US, INC. | $24.88 | 2023 | Opsumit |
| Lexicon Pharmaceuticals, INC. | $21.40 | 2023 | Inpefa |
| Philips North America LLC | $14.68 | 2019 | |
| Chiesi USA, INC. | $12.20 | 2019 | |
| Abiomed | $11.44 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joshua Krasnow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.